Jefferies Financial Group Inc. purchased a new position in Bio-Techne Corp (NASDAQ:TECH – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,738 shares of the biotechnology company’s stock, valued at approximately $1,141,000.
Several other institutional investors have also recently made changes to their positions in the stock. Tema ETFs LLC lifted its position in shares of Bio-Techne by 5.4% during the 2nd quarter. Tema ETFs LLC now owns 2,818 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 145 shares in the last quarter. ZWJ Investment Counsel Inc. increased its holdings in Bio-Techne by 4.8% in the 3rd quarter. ZWJ Investment Counsel Inc. now owns 3,971 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 183 shares in the last quarter. Empirical Finance LLC increased its holdings in Bio-Techne by 4.4% in the 2nd quarter. Empirical Finance LLC now owns 4,478 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 189 shares in the last quarter. North Dakota State Investment Board increased its holdings in Bio-Techne by 4.3% in the 3rd quarter. North Dakota State Investment Board now owns 4,789 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 196 shares in the last quarter. Finally, Parallel Advisors LLC increased its holdings in Bio-Techne by 13.2% in the 1st quarter. Parallel Advisors LLC now owns 1,936 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 225 shares in the last quarter. Institutional investors own 98.95% of the company’s stock.
Bio-Techne Stock Performance
Shares of Bio-Techne stock traded down $0.04 during trading hours on Friday, hitting $72.80. The company’s stock had a trading volume of 2,491,007 shares, compared to its average volume of 2,932,330. The business has a 50 day moving average price of $72.53 and a two-hundred day moving average price of $63.48. Bio-Techne Corp has a 12-month low of $43.19 and a 12-month high of $72.88. The company has a market cap of $11.44 billion, a PE ratio of 66.79, a PEG ratio of 5.28 and a beta of 1.29.
Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The biotechnology company reported $0.44 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.44. Bio-Techne had a return on equity of 13.00% and a net margin of 13.95%. The firm had revenue of $299.71 million during the quarter, compared to analyst estimates of $292.60 million. As a group, research analysts anticipate that Bio-Techne Corp will post 1.75 earnings per share for the current year.
Bio-Techne Cuts Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, November 23rd. Shareholders of record on Friday, November 13th will be paid a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 13th. This is a negative change from Bio-Techne’s previous quarterly dividend of $0.65. Bio-Techne’s dividend payout ratio is currently 29.36%.
Analysts Set New Price Targets
TECH has been the topic of a number of recent analyst reports. Argus cut shares of Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a research note on Monday, October 26th. Zacks Research raised shares of Bio-Techne from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 29th. Weiss Ratings upgraded shares of Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Benchmark reissued a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. Finally, Wells Fargo & Company cut shares of Bio-Techne from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $62.00 to $73.00 in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $68.92.
Check Out Our Latest Analysis on TECH
About Bio-Techne
Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.
Featured Articles
- Five stocks we like better than Bio-Techne
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
